secretase


Also found in: Thesaurus, Medical, Wikipedia.

se·cre·tase

 (sē′krə-tās′, -tāz′)
n.
Any of three subtypes of a protease located in cell membranes of the brain. In Alzheimer's disease, a secretase (designated beta) degrades amyloid precursor protein into beta-amyloid peptides that accumulate to form amyloid plaques.

ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.secretase - a set of enzymes believed to snip pieces off a longer protein producing fragments of amyloid protein that bunch up and create amyloid protein plaques in brain tissue (the pathological hallmark of Alzheimer's)
enzyme - any of several complex proteins that are produced by cells and act as catalysts in specific biochemical reactions
References in periodicals archive ?
NASDAQ: JUNO) has inked three license agreements to advance its programme in multiple myeloma using gamma secretase inhibitors in combination with BCMA-directed CAR T cells, the company said.
announced today that the latest data on its oral dual orexin receptor antagonist lemborexant and its oral beta secretase cleaving enzyme (BACE) inhibitor elenbecestat will be presented at the 10th Clinical Trials on Alzheimer's Disease (CTAD), taking place in Boston, the United States, from November 1 to 4.
The compound deters beta secretase enzyme BACE 1 related to the create of beta amyloid.
announced today that enrollment has commenced in MISSION AD, a Phase III clinical program of the beta secretase cleaving enzyme (BACE) inhibitor E2609 in patients with early Alzheimer's disease in the United States.
An important number of the mutations occur at the secretase cleavage site or in the transmembrane domain.
With regard to APP intracellular processing, both secretases ([alpha]- and [beta]-) have been identified in the ER together with [gamma]-secretase which is present in mitochondria-associated membrane (MAM) subcompartment [48, 68].
Research over the last few years indicates that a misregulation of the secretase cleavage in Alzheimer's results in inadequate production of protective APPsα.
and AstraZeneca have entered an agreement to co-develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor in development as a potential treatment for Alzheimer's disease (AD).
Both the AstraZeneca and Merck medicines work by blocking an enzyme called beta secretase that is involved in production of beta-amyloid, a protein that creates brain plaques considered a major cause of Alzheimer's disease.
Discovery of the [beta]- and [gamma]-secretase substrates calls for precaution concerning the anti-A[beta] production strategy targeted at the secretases: chronic and over-inhibition of the secretases is likely to cause adverse side-effects.
Identification of two novel synaptic gamma- secretase associated proteins that affect amyloid beta-peptide levels without altering Notch processing.
Recent research has revealed mutations at what is called the 'beta secretase site'--the point where BACE1 cuts the amyloid precursor," says Dr.